Teevir Tablet (Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate)

Teevir Tablet is an antiretroviral medicine which is used to treat HIV (human immunodeficiency virus) infection as prescribed by the doctor. Teevir is a combination of three antiviral medicines including emtricitabine, tenofovir disoproxil fumarate and efavirenz. It works by reducing viral load in the body and multiplication of the virus to control the infection. Take it as prescribed by the doctor.

HIV

Like any other medicine Teevir Tablet(Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate) also shows some side effects. Some of the mild ones do not need any medical attention, and they go away as the body adapts to the medicine. It is important to consult your doctor if they persist for a longer time and are deteriorating your health.
Common side effects include:
● Nausea
● Diarrhea
● Rash
● Decreased white blood cell count (neutrophils)
● Vomiting
● Abdominal pain
● Allergic reaction
● Fatigue
● Increased lipase in the blood
● Headache
● Insomnia (difficulty sleeping)
● Depression
● Dizziness
● Abnormal dreams
● Nasopharyngitis (inflammation of the throat and nasal passages)
● Upper respiratory tract infection
● Anxiety
● Sinus inflammation

Take Teevir Tablet(Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate) in dosage as prescribed by the doctor. Dosage and the duration determined as per the patients health condition. This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken on an empty stomach. Never skip a dose or double dose.

● Sax, P. E., DeJesus, E., Mills, A., Zolopa, A., Cohen, C., Wohl, D., ... & Cheng, A. K. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. The Lancet, 379(9835), 2439-2448.
● DeJesus, E., Young, B., Morales-Ramirez, J. O., Sloan, L., Ward, D. J., Flaherty, J. F., ... & AI266073 Study Group. (2009). Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 51(2), 163-174.
● Frampton, J. E., & Croom, K. F. (2006). Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs, 66(11), 1501-1512.
● Lockman, S., Brummel, S. S., Ziemba, L., Stranix-Chibanda, L., McCarthy, K., Coletti, A., ... & Whalen, F. (2021). Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet, 397(10281), 1276-1292.
● Venter, W. D., Sokhela, S., Simmons, B., Moorhouse, M., Fairlie, L., Mashabane, N., ... & Hill, A. (2020). Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet HIV, 7(10), e666-